GlassScriptPhysician profile
Howard L Rice
NPI 1114927134
$5,700.36
in general payments reported to CMS, 2019-2025
20 companies · $87.67 in 2025
The $87.67 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $776 · 2021: $1,367 · 2022: $420 · 2023: $625 · 2024: $915 · 2025: $87.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127 · Travel and Lodging: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.37 |
| Travel and Lodging | $500.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,843.89 | 2019-2025 | Dovato, Apretude, Rukobia |
| Gilead Sciences, INC. | $1,424.24 | 2019-2025 | |
| Janssen Biotech, INC. | $281.47 | 2019-2023 | Symtuza |
| Janssen Products, LP | $211.75 | 2019 | |
| Insmed, INC. | $205.68 | 2019 | |
| Merck Sharp & Dohme LLC | $129.14 | 2019-2023 | Recarbrio, Dificid, Zerbaxa |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 | |
| Amgen INC. | $77.34 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $67.64 | 2021-2023 | Nuzyra |
| Theratechnologies INC. | $54.60 | 2023 | Egrifta, Trogarzo |
| Abbvie INC. | $51.25 | 2021 | |
| Janssen Scientific Affairs, LLC | $44.72 | 2019-2023 | Symtuza |
| Nabriva Therapeutics, Plc | $43.52 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $35.79 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $21.22 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $20.39 | 2023 | Rezzayo, Vabomere, Kimyrsa |
| Pfizer INC. | $18.23 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.42 | 2019 | |
| Shionogi INC | $15.10 | 2023 | Fetroja |
| Inspire Medical Systems, INC. | $13.98 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.